RON HOOGEVEEN to Cholesterol, LDL
This is a "connection" page, showing publications RON HOOGEVEEN has written about Cholesterol, LDL.
Connection Strength
2.796
-
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin Chem. 2021 01 08; 67(1):143-153.
Score: 0.550
-
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
Score: 0.463
-
Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
Score: 0.341
-
The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013; 2013:729515.
Score: 0.337
-
Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy. Circulation. 2012 Sep 25; 126(13):1577-86.
Score: 0.308
-
Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2021 03; 41(3):1229-1238.
Score: 0.138
-
ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
Score: 0.122
-
A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics. 2016 04; 17(6):583-91.
Score: 0.099
-
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
Score: 0.084
-
Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
Score: 0.064
-
Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003 Aug; 146(2):227-33.
Score: 0.041
-
Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project. Atherosclerosis. 2023 02; 367:15-23.
Score: 0.040
-
Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
Score: 0.038
-
Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res. 2001 Apr; 42(4):631-8.
Score: 0.035
-
Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014 Dec; 2(6):600-7.
Score: 0.022
-
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015 Jan 24; 385(9965):351-61.
Score: 0.022
-
Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014 Feb 06; 94(2):198-208.
Score: 0.021
-
Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study. Am J Epidemiol. 2013 Oct 01; 178(7):1076-84.
Score: 0.021
-
Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study. Thromb Res. 2013 Jul; 132(1):44-6.
Score: 0.020
-
Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis. 2011 Dec; 219(2):596-602.
Score: 0.018
-
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005 Nov 28; 165(21):2479-84.
Score: 0.012